Recent developments for Calidi Biotherapeutics include clinical trial initiations, capital raises, leadership appointments, and regulatory clearances advancing its cancer immunotherapy pipeline.

• Calidi partnered with Avance Clinical to initiate the CLD-401 trial in Australia, marking a key step in clinical development [N1].
• The company closed a $6 million offering in March 2026 to advance its cancer immunotherapy pipeline [N2].
• Calidi priced a $5.2 million public offering of shares and warrants in March 2026 to support its pipeline [N3].
• Reported a 23% reduction in net loss for fiscal Q2 2025, indicating some operational progress [N4].
• Hosted a webinar on precision genetic medicine advances in July 2025 to engage investors and highlight scientific progress [N5].
• Announced an agreement for immediate exercise of warrants, anticipating $4.6 million in proceeds in July 2025 [N6].
• Strengthened leadership team with new CEO and Chief Medical Officer appointments in May 2025 [N7].
• Received FDA IND clearance for CLD-201 in solid tumor treatment in April 2025 [N8].

Calidi Biotherapeutics has advanced its clinical pipeline with FDA IND clearance for CLD-201 and initiation of clinical trials for CLD-101 and CLD-401, demonstrating progress in its cancer immunotherapy programs. The company has strengthened its leadership with experienced executives, which may enhance strategic execution. Recent successful capital raises totaling over $11 million in early 2026 provide funding to support ongoing research and development activities. Its focus on oncolytic virus therapies addresses unmet needs in oncology, potentially positioning it for future licensing or commercialization opportunities [N1][N2][N3][N7][N8][S1].

Calidi Biotherapeutics operates in a high-risk, early-stage biotechnology sector with no current commercial revenues and significant accumulated losses. The company reported a net loss of approximately $19.9 million in 2025 and has noted substantial doubt about its ability to continue as a going concern without additional funding. Clinical development programs face long timelines, regulatory uncertainties, and potential failure risks. The company’s financial position requires ongoing capital raises, which may dilute existing shareholders. Market competition, regulatory hurdles, and operational challenges typical of emerging biotech firms present material risks to business continuity and value realization [S1].

Calidi Biotherapeutics' moat is primarily based on its proprietary oncolytic virus technology platforms and its pipeline of cancer immunotherapy candidates. The company’s focus on novel therapies for difficult-to-treat cancers such as glioma and solid tumors positions it in a specialized niche within oncology. Its leadership team includes experienced executives with backgrounds in biotechnology and drug development. However, as a clinical-stage company without commercial products or revenues, its competitive advantage depends on successful clinical development, regulatory approvals, and eventual market acceptance. Intellectual property protection and ongoing innovation in its therapeutic platforms contribute to its potential moat, but these remain subject to the inherent risks of early-stage biotech development [S1][N7].

• Clinical Development Risk: The company’s product candidates are subject to long development cycles and may fail in preclinical or clinical trials, which could delay or prevent regulatory approval and commercialization.
• Financial Risk: Calidi has experienced recurring losses and negative cash flows, with substantial doubt about its ability to continue as a going concern without raising additional capital.
• Regulatory Risk: Obtaining regulatory approvals for product candidates is uncertain and may require significant time and resources.
• Market and Competitive Risk: The biotechnology industry is highly competitive with rapid technological changes, and competitors may develop superior therapies.
• Operational Risk: Dependence on key personnel and the ability to protect proprietary technology are critical to the company’s success.

• Calidi Biotherapeutics, Inc. is an emerging growth biotechnology company focused on developing cancer immunotherapy and oncolytic virus therapies through research, development, and clinical trials [S1].
• The company operates as a single reportable segment managing research, development, and commercialization efforts of platforms to potentiate oncolytic virus therapies [S1].
• Calidi has not generated any revenues from commercial products to date [S1].
• The company expects to generate future income from license fees, funded R&D agreements, milestone payments, product sales, government and third-party funding, and royalties, contingent on regulatory approval and commercialization success [S1].
• Calidi has a pipeline including product candidates such as CLD-101 for recurrent glioma, CLD-201 for solid tumor treatment, and CLD-401 with clinical trials initiated or planned in the US and Australia [N1][N8][S1].
• The company received FDA IND clearance for CLD-201 in solid tumor treatment [N8].
• Calidi has initiated recruitment for the CLD-101 clinical trial targeting high-grade glioma [N1][S1].
• The company has strengthened its leadership team with appointments of a new CEO, Eric Poma, Ph.D., and Chief Medical Officer, Guy Travis Clifton, in 2025 [N7][S1].
• Calidi has conducted multiple public offerings and financings, including a $6 million offering in March 2026 and a $5.2 million public offering of shares and warrants in March 2026 to advance its cancer immunotherapy pipeline [N2][N3].
• The company has experienced recurring net losses, with a net loss of approximately $19.9 million for the year ended December 31, 2025, and an accumulated deficit of $141.6 million as of that date [S1].
• Basic and diluted net loss per share was $5.95 for the year ended December 31, 2025 [S1].
• Calidi had cash and cash equivalents of approximately $9.6 million as of December 31, 2024, and current assets of $6.3 million with current liabilities of $3.9 million as of December 31, 2025, resulting in a current ratio of 1.59 and a cash ratio of 2.44 [S1].
• The company has no significant exposure to market risk from interest rate changes or foreign currency exchange rates currently, but operates subsidiaries in Germany and Australia which may expose it to currency fluctuations in the future [S1].
• Calidi is classified as a smaller reporting company and an emerging growth company, which provides it certain reduced disclosure and reporting requirements under SEC regulations [S1].
• The company’s internal controls and disclosure controls were evaluated as effective as of December 31, 2025 [S1].
• Calidi’s operations include research, clinical development, and manufacturing process development for preclinical and clinical trials, with long development cycles and risks typical of early-stage biotechnology companies [S1].
• The company’s financial statements are prepared on a going concern basis, with management noting substantial doubt about the ability to continue as a going concern within 12 months from the date of issuance of the consolidated financial statements, dependent on raising additional funding [S1].